Navigation Links
Watson and Richter Announce Exclusive License Agreement for Esmya™
Date:12/16/2010

t Limited. The Watson brand pipeline portfolio includes a number of products, including Prochieve®, under development with Columbia Laboratories for prevention of pre-term birth in women with a short cervix, recombinant follicle stimulating hormone (rFSH) in development with Itero Biopharmaceuticals for female infertility, and three novel new contraceptives.  

For press release and other company information, visit Watson Pharmaceuticals' Web site at www.Watson.com.

Forward-Looking StatementStatements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of product development efforts, including FDA and other regulatory approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson, its subsidiaries, and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2009 and Watson's quarterly report on
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... provider of injectable drugs and infusion technologies, today announced ... 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, ... is scheduled to begin at 10:30 a.m. Pacific time ... to all interested parties through a live audiocast accessible ...
(Date:12/19/2014)... Colo. , Dec. 19, 2014  Monarch America ... Cannabis Kinetics Corp.) is pleased to provide this review ... continued growth in 2015. "Over this past ... goals and I am extremely proud to say that ... position today than it has ever been," stated ...
(Date:12/19/2014)... -- Somewhere between dropping five pounds and cooking more ... Audicus , a next-generation hearing aids company, will help ... Hearing loss is the third most common chronic ... often unaddressed. Forty-eight million Americans have hearing loss, but ... due to price. Hearing aids traditionally cost $7,000 per ...
Breaking Medicine Technology:Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Audicus Will Help People Resolve to Hear Better in 2015 2
... 2010 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... to offer its common stock in a registered public offering ... Act of 1933. Stereotaxis also intends to grant the underwriters ... common stock to cover over-allotments, if any. Stereotaxis ...
... 10, 2010 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, ...   Interested parties may access a live webcast ... It is recommended that listeners log on 15 ...
Cached Medicine Technology:Stereotaxis Announces Public Offering of Common Stock 2Stereotaxis Announces Public Offering of Common Stock 3Stereotaxis Announces Public Offering of Common Stock 4Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:12/21/2014)... As testosterone therapy lawsuit filings ... and blood clots from using testosterone products such as ... shows that the male hormone testosterone may increase the ... published in the Proceedings of the National Academy of ... group of male rats with naturally occurring colon cancer. ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly ... announced its bamboo flooring promotion for the coming ... certified suppliers, and offers the best bamboo products ... current promotion, all customers can enjoy a special ... they know BambooIndustry.com from press releases. , The ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 DePuy ... a metal-on-metal version of the artificial hip system ... state and federal courts, Bernstein Liebhard LLP reports. ... Bergen County Superior Court on December 2nd, counsel ... begin deposition of plaintiffs on November 19, 2014, ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... Founder and CEO Andrew Levitt to showcase HealthTalker at ,Health ... ... Somerville, MA (PRWEB) October 14, 2008 -- HealthTalker, www.healthtalker.com ... biotechnology industries, today announced that Andrew Levitt, Founder and CEO ...
... bus featuring candidates, ,healthcare report card, ... also mail, ... activists pledge to educate voters on ... healthcare proposals, LAS VEGAS, Oct. 14 This week, ... country launched a drive,to make sure voters in Nevada, Ohio, ...
... the eve of the last,Presidential debate, the Latino Commission ... AIDS Awareness Day (NLAAD) to Senators John,McCain and Barack ... of,the United States to bring HIV prevention and care ... Puerto Rico," stated Dennis,DeLeon, President of the Latino Commission ...
... OCTOBER 14, 2008 Late-breaking results ... Radio Contrast Nephropathy in Patients Undergoing Diagnostic ... the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) ... Foundation (CRF). , The prospective, randomized, ...
... Oct. 14, 2008 Adding corticosteroids to ... recover more quickly than with antibiotics alone, UT ... Unlike the anabolic steroids used to bulk up ... related to infectious diseases, such as bacterial meningitis. ...
... restrict,abortion, WASHINGTON, Oct. 14 A new nationwide ... handed down its decision,in Roe v. Wade, public support ... pregnancy stands at just 8%. The poll was,conducted for ... of,Public Opinion between September 24 and October 3, 2008, ...
Cached Medicine News:Health News:HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' 2Health News:National RN Union Launches Multi-State Drive for Healthcare Voters With Road Show in Nevada, October 13 Through 17 2Health News:The Latino Commission on AIDS Call on Presidential Candidates to Honor National Latino AIDS Awareness Day on October 15 2Health News:Late-breaking results of clinical trial on therapeutic endovascular cooling reported at TCT 2008 2Health News:Steroids aid recovery from pneumonia, UT Southwestern researchers say 2Health News:Nationwide Poll Shows 84% of Americans Favor Significant Restrictions on Abortion 2
... 30 years, Digisonics has set the ... the first review station, the only ... the best multi-modality reporting., ,DigiView cardiology ... review workstations, professional reporting choices, an ...
... Rapid measurement of colloid osmotic (oncotic) ... onset in clinical situations. Uses a ... chambers to simulate the role of ... establishment of osmotic pressure responsible for ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
Medicine Products: